Fostemsavir (BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529). It is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs. Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs. Since gp120 is a highly conserved area of the virus, the drug is unlikely to promote resistance to itself via generation of CD4-independent virus.

CAS：864953-29-7
中文别名：
英文别名：CS-1059;UNII-97IQ273H4L;[3-[(4-benzoylpiperazin-1-yl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate;1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine;
分子式：C25H26N7O8P
分子量：583.49
精确质量：583.158
Psa：192.02
Logp：1.0439

密度：1.6±0.1g/cm3
沸点：904.1±75.0°Cat760mmHg
闪点：500.6±37.1°C
蒸汽压：0.0±0.3mmHgat25°C
折射率：1.723
储存条件：-20°C，密闭，干燥